This will play a video - Doctor visiting patient with white beard

SYMPTOMATIC AORTIC STENOSIS TIMING IS EVERYTHING

Urgent Referral can save lives.

CONTACT US FOR MORE INFORMATION

350,000 Est. Incidence

Today, 350,000 people in Western Europe develop annually symptomatic severe aortic stenosis (SSAS).1-9

Download Brochure
Aortic Stenosis Data
Medtronic transcatheter aortic valve replacement (TAVR) infographic noting that once severe symptoms of symptomatic aortic stenosis appear, survival is cut short.

MEDICAL MANAGEMENT ISN’T ENOUGH

After developing symptomatic severe aortic stenosis, the average patient survival is two years without treatment.12 

SYMPTOMATIC AORTIC STENOSIS CAN BE FATAL

Aortic stenosis is among the most common of all valvular heart diseases and continues to increase as our population ages.13 
Symptomatic severe aortic stenosis (SSAS) can be fatal if left untreated.

EARLY DIAGNOSIS AND TREATMENT CAN MEAN BETTER OUTCOMES

Stethoscope image on the Medtronic transcatheter aortic valve replacement (TAVR) page.

DUE TO THE FOLLOWING FACTORS, SSAS ISN'T ALWAYS EASY TO DIAGNOSE:

  • Heart murmurs go undetected.14
  • Referrals are delayed or too late.14
  • Echocardiogram findings are misclassified due to complex cardiac anatomy.14
  • Patients don't recognise or report their symptoms.15
  • Patients refuse treatment.16
Medtronic TAVR graph noting the operated versus unoperated survival rates of aortic valve replacement over a 5-year span.

AORTIC VALVE REPLACEMENT GREATLY IMPROVES THE RATE OF SURVIVAL

Mortality difference for people with symptoms of aortic stenosis treated with aortic valve replacement versus those not undergoing this procedure is one of the most striking in medicine.17

URGENCY IS EVERYTHING FOR SYMPTOMATIC AORTIC STENOSIS PATIENTS

MIND THE MURMUR

You can help save more lives by recognising the symptoms of SSAS early on.

Remember to: 

1 Listen for the murmur.

2 Order an echocardiogram.

3 Refer patient to a heart valve team without delay.

REFER YOUR SEVERE AORTIC STENOSIS 
PATIENTS
TO THE HEART VALVE TEAM

FOLLOW 2021 ESC/EACTS GUIDELINES

Class 1B recommendation for intervention: Patients with symptomatic severe high-gradient aortic stenosis, low-flow, low-gradient aortic stenosis with reduced ejection fraction, AND evidence of flow reserve.
Class 1B and 1C recommendation for intervention: Expanded to asymptomatic severe aortic stenosis patients, considering a careful heart team evaluation of their treatment need.18

DOWNLOAD 2021 ESC/EACTS GUIDELINES SUMMARY

Current evidence reinforces the critical role of the Heart Team, which should integrate clinical, anatomical, and procedural characteristics beyond conventional scores, and informed patient’s treatment choice.18

2021 ESC/EACTS Valvular Heart Disease Guidelines
Male doctor smiling while visiting old lady
Image of patient data

MISSING HEART VALVE DISEASE AWARENESS

According to the European Heart Health Survey only 6% of people over the age of 60 years can correctly describe aortic valve stenosis. In addition the respondents were less concerned about heart valve disease than with cancer.19

UNDERSTANDING SYMPTOMATIC AORTIC STENOSIS FROM A PATIENT POINT OF VIEW

It's easier to help patients when you know what they're thinking. The insights gathered from a new national survey conducted by Heart-Valve-Surgery.com, with support from Medtronic, can help you better understand the heart valve patient experience.

Doctors standing together in a group and smiling at camera.

Share this resource with your patients

AorticValveTreatment.com can help them learn more about their condition and find a supportive community of other patients diagnosed with severe aortic stenosis.

EXPLORE NOW

CLINICAL EVIDENCE TRANSCATHETER AORTIC VALVE IMPLANTATION (TAVI)

Learn more about the multiple clinical trials and their outcomes.

Discover Here

Fill in the form below to contact us

*Indicates Required Field

Your information will be processed and protected in accordance with our privacy statement

Selecting “no” to marketing emails above will not affect your other email selections, and a Medtronic representative will still reach out via email, if selected. Your personal data will used to manage your relationship with Medtronic, and, if you consent, to provide you with relevant email updates based on your user preferences. You can opt-out of receiving such emails at any time by clicking the unsubscribe link in the relevant email. Medtronic may use pixels and other technologies in emails to gather statistics around email opening and clicks, to help us improve our communications and to provide you with relevant content. For more information, see the Medtronic privacy notice.

You can always change your preferences or update your personal details by visiting the Preference center.

See the Preference center

*

The European Heart Health Survey was conducted 2019, including a total of 12'832 people aged ≥ 60 years in 11 European countries.

*

The European Heart Health Survey was conducted 2019, including a total of 12'832 people aged ≥ 60 years in 11 European countries.

1

STS Adult Cardiac Database. 2010 Harvest, Isolated AVR.

2

Bach DS, Cimino N, Deeb GM. Unoperated patients with severe aortic stenosis. J Am Coll Cardiol. November 13, 2007;50(20):2018-2019.

3

Pellikka PA, Sarano ME, Nishimura RA, et al. Outcome of 622 adults with asymptomatic, hemodynamically significant aortic stenosis during prolonged follow-up. Circulation. June 21, 2005;111(24):3290-3295.

4

Charlson E, Legedza AT, Hamel MB. Decision-making and outcomes in severe symptomatic aortic stenosis. J Heart Valve Dis. May 2006;15(3):312-321.

5

Nkomo VT, Gardin JM, Skelton TN, Gottdiener JS, Scott CG, Enriquez-Sarano M. Burden of valvular heart diseases: a population-based study. Lancet. September 16, 2006;368(9540):1005-1011.

6

Lindroos M, Kupari M, Heikkilä J, Tilvis R. Prevalence of aortic valve abnormalities in the elderly: an echocardiographic study of a random population sample. J Am Coll Cardiol. April 1993;21(5):1220-1225.

7

Mack MJ, Brennan JM, Brindis R, et al. Outcomes following transcatheter aortic valve replacement in the United States. JAMA. November 20, 2013;310(19):2069-2077.

8

Medtronic data on file #1. 

9

lung B, Baron G, Butchart EG, et al. A prospective survey of patients with valvular heart disease in Europe: The Euro Heart Survey on Valvular Heart Disease. Eur Heart J. July 2003;24(13):1231-1243. 

10

Durko AP, Osnabrugge RL, Van Mieghem NM, Milojevic M, Mylotte D, Nkomo VT, Pieter Kappetein A. Annual number of candidates for transcatheter aortic valve implantation per country: current estimates and future projections. Eur Heart J. 2018 Jul 21;39(28):2635-2642. doi: 10.1093/eurheartj/ehy107. PMID: 29546396.

11

Everett RJ, et al. Timing of intervention in aortic stenosis: a review of current and future strategies. Heart Epub 2018 doi:10.1136/heartjnl-2017-312304

12

Modified from Lester SJ, Heilbron B, Gin K, Dodek A, Jue J. The natural history and rate of progression of aortic stenosis. Chest. April 1998;113(4):1109-1114.

13

Carabello BA, Paulus WJ. Aortic stenosis. Lancet. March 14, 2009;373(9667):956-966.

14

McCarthy CP, Phelan D, Griffin B. When does asymptomatic aortic stenosis warrant surgery? Assessment techniques. Cleve Clin J Med. April 2016;83(4):271-280.

15

Brennan JM. Under-treatment of Aortic Stenosis in the United States. Presented at TVT 2019; Chicago, IL.

16

Medtronic data on file #2.

17

Schwarz F, Baumann P, Manthey J, et al. The effect of aortic valve replacement on survival. Circulation. November 1982;66(5):1105-1110. 

18

Vahanian, A., Beyersdorf, F., et al. (2021), 2021 ESC/EACTS Guidelines for the management of valvular heart disease: Developed by the Task Force for the management of valvular heart disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery European Heart Journal, 2021;, ehab395, https://doi.org/10.1093/eurheartj/ehab395.

19

Gaede L, Sitges M, Neil J, et al. European heart health survey 2019. Clin Cardiol. 2020;1–8. https://doi.org/10.1002/clc.23478